The Global Coalition of TB Activists (GCTA) along with its country partners For Impact in Social Health (FIS), Touched by TB, POP TB Indonesia, and Socios En Salud will host a virtual event for the launch of 'Activating a human rights-based TB response – a technical brief for policymakers and program implementers' in 5 languages to further a people-centered rights-based TB response.

On 12 August 2021, TB Alliance will host a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

A new deep learning model rivaled radiologists’ accuracy at assessing tuberculosis on chest X-rays. The tool may prove particularly useful for triaging patients in low-resource settings.

TB Alliance launched a webpage to provide information on national-level access to the BPaL regimen - a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

TB Alliance and KNCV Tuberculosis Foundation published a study in BMC Public Health, focused on collecting stakeholder views (in Nigeria, Indonesia, and Kyrgyzstan) regarding the acceptability, feasibility, and likelihood of stakeholders implementing the BPaL regimen. BPal is a three-drug, 6-month, all-oral regimen composed of bedaquiline, pretomanid and linezolid for the treatment of highly drug-resistant forms of TB.

August 4, 2021 – Published today, Tackling TB Stigma, a new comprehensive and community-driven report, shows that taking a wraparound approach to health care for newcomers, including hyper-local strategies to deal with stigma around diseases, is the best way to ensure people can address their health issues as soon as possible, and in comprehensive ways. Tuberculosis (TB), and especially the stigma related to the disease, including stigma based in people’s countries of origin, and stigma that’s pervasive here in Canada. The report is published by Access Alliance Multicultural Health and Community Services, a community health centre in Toronto serving refugee and other newcomer populations in many areas across Canada’s largest city.

The Hague / Geneva, 4 August 2021 – A large global study which aims to determine if digital adherence technologies (DATs) can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.

The Stop TB Partnership’s Global Drug Facility (GDF) announced the inclusion in its catalog, for the first time ever, of two ultra-portable digital X-ray systems and two software packages for the computer-aided detection of TB based on artificial intelligence. These important digital tools to combat TB will be made available at a reduced cost to all TB programs in low- and middle-income countries.

Take a quick Community Advisory Board (CAB) compensation survey and help define how to best support CAB members!

For 70 years, clinicians thought they knew the shape of tuberculosis granulomas in the lungs of patients. Histology — the study of microscopic structures in thin slices of lung tissue in the 1940s and 1950s — showed round features, and researchers intuitively assumed that meant the granulomas were spherical or ovoid.